Video

Dr. Freedland on Standardized PSA Testing in Prostate Cancer

Stephen J. Freedland, MD, discusses the importance of standardizing prostate-specific antigen testing in prostate cancer.

Stephen J. Freedland, MD, Warschaw Robertson Law Families Chair in Prostate Cancer, director, Center for Integrated Research in Cancer and Lifestyle, co-director, Cancer Genetics and Prevention Program, associate director, Faculty Development Samuel Oschin Comprehensive Cancer Institute, and professor of surgery, Cedars-Sinai Medical Center, discusses the importance of standardizing prostate-specific antigen (PSA) testing in prostate cancer.

In clinical trials, established time points for PSA are needed. However, there may not be a survival difference among patients who are discovered to have a rising PSA within 1 month of each other, so it’s reasonable to test PSA every 3 or 4 months, or even every 6 weeks in clinical practice, says Freedland.

Regardless of what time point patients undergo PSA testing, it is important that they undergo consistent testing with added follow-up, adds Freedland. Notably, some patients with undergo the first PSA test and come back 2 years later, which puts them at risk of developing progressive disease, concludes Freedland.

Related Videos
Funda Meric-Bernstam, MD
Bhavana Pothuri, MD
Kristen Spencer, DO
Laurence Albigès, MD, PhD
Nirav Shah, MD, MSHP, discusses evaluating zamtocabtagene autoleucel in patients with relapsed/refractory diffuse large B-cell lymphoma.
Bhagirathbhai Dholaria, MBBS
Sairah Ahmed, M.D
Joshua K. Sabari, MD
Barry W. Goy, MD
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center